Carlyle-backed animal health company SeQuent Scientific and Viyash Life Sciences have announced a ₹8,000 crore merger to create a platform, which will be one of India's largest in animal pharmaceuticals.
“To continue to deliver differentiated value to our customers in times to come, it is imperative to scale up our product development and research and development (R&D) capabilities to capture the market opportunity we are seeing and to build on our leadership in the animal health market,” said Sequent Chief Executive Officer (CEO) Rajaram Narayanan.
Viyash founder and CEO Haribabu Bodepudi, who was chief operating officer of global drug major Mylan (now known as Viatris), said: “With our combined resources, R&D capabilities, manufacturing capacities, and streamlined supply chain, we are well positioned to accelerate growth and offer a wider range of high-quality products to our customers.”
A senior analyst who tracks Sequent told Business Standard the merger would not have an impact on the Indian animal health industry because Viyash makes human active pharmaceutical ingredients (APIs).
This story is from the September 28, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the September 28, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
NPS FUND RETURNS Equity-debt allocation: Let risk appetite, not past-yr returns, decide
Funds under the National Pension System (NPS) have delivered strong returns over the past year across all asset classes, exceeding their longer-term averages.
Index AUM criteria to limit MF Lite's ambit
The strict product launch conditions under the MF Lite framework leaves little room for innovation by asset managers opting for this newly introduced route to enter the mutual fund (MF) business, experts said.
Mumbai realty firms to build on demand, robust pipeline
The outlook for Mumbai-based real estate players remains strong given the launch pipeline and demand outlook reflected in the registration data for December.
Mkts open in green for 7th year running
2025 OUTLOOK: Face headwinds from high valuations, domestic demand issues, and global uncertainties
Sebi simplifies disclosure norms for listed entities with integrated filing
The Securities and Exchange Board of India (Sebi) has made integrated filing for Listing Obligations and Disclosure Requirements (LODR) effective for all disclosures starting with the quarter ending December 2024.
Stock Consolidates, Outlook Bright
With just two trading sessions to go before the ITC-ITC Hotels demerger record date, shares of ITC continue to consolidate in a thin range of ₹460-485 in an otherwise volatile equity market.
NSE enforces mechanism for brokers to curb market abuse
The National Stock Exchange (NSE) has issued a guidance note for stock brokers to ensure prevention and detection of fraud or market abuse.
ITC Hotels to go the Jio Fin way
ITC's move to hive off its hotel business will have implications for passive funds and exchange traded funds (ETFs) similar to that seen during the Reliance Industries-Jio Financial demerger.
Air India Becomes 1st Indian Airline to Offer Wi-Fi on Domestic Flights
The in-flight Wi-Fi will allow flyers to connect multiple devices simultaneously when above 10,000 feet in the air
2024 Warmest Year in India Since 1901: IMD
The year 2024 was the warmest on record in India since 1901, with the average minimum temperature settling 0.90 degrees Celsius above the long-period average, the India Meteorological Department (IMD) said on Wednesday.
